Insulin resistance in Alzheimer's disease

Neurobiology of Disease

Volumn 72, Issue Part A, 2014, Pages 92-103

  Dineley, Kelly T ^a   Jahrling, Jordan B ^a,b   Denner, Larry ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Alzheimer's disease; Animal models; Cognitive function; ERK; Insulin resistance; Learning and memory; Metabolism; Mitochondria; PPAR gamma; Therapeutic windows

Indexed keywords

AMYLIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; CEREBROLYSIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUCAGON LIKE PEPTIDE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INSULIN SENSITIZING AGENT; LEPTIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PRESENILIN 1; PRESENILIN 2; RESVERATROL; ROSIGLITAZONE;

ALZHEIMER DISEASE; AMYLOIDOSIS; AUTOSOMAL DOMINANT INHERITANCE; BLOOD BRAIN BARRIER; CHRONIC INFLAMMATION; COGNITIVE DEFECT; ENVIRONMENTAL ENRICHMENT; ENVIRONMENTAL FACTOR; GENE MUTATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; LEARNING; LONG TERM POTENTIATION; MEMORY; METABOLIC STRESS; MILD COGNITIVE IMPAIRMENT; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; POSITIVE FEEDBACK; REVIEW; ANIMAL; BRAIN; DISEASE MODEL; ENCEPHALITIS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; ENCEPHALITIS; HUMANS; INSULIN; INSULIN RESISTANCE; LEARNING; MAP KINASE SIGNALING SYSTEM; PPAR GAMMA;

EID: 84909606636     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.09.001     Document Type: Review

References (261)

1. Adler B.L., et al. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. Neurobiol. Aging 2014, 35:793-801.
2. Akama K.T., Van Eldik L.J. Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta- and tumor necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor- and NFkappaB-inducing kinase-dependent signaling mechanism. J. Biol. Chem. 2000, 275:7918-7924.
3. Akomolafe A., et al. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch. Neurol. 2006, 63:1551-1555.
4. Albert M.S., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:270-279.
5. Ali S., Fonseca V. Overview of metformin: special focus on metformin extended release. Expert. Opin. Pharmacother. 2012, 13:1797-1805.
6. Arvanitakis Z., et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 2004, 61:661-666.
7. Atkins C.M., et al. The MAPK cascade is required for mammalian associative learning. Nat. Neurosci. 1998, 1:602-609.
8. Baker L.D., et al. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch. Neurol. 2011, 68:51-57.
9. Bales K.R. The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update. Expert Opin. Drug Discov. 2012, 7:281-297.
10. Bales K.R., et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:15233-15238.
11. Balietti M., et al. Early selective vulnerability of synapses and synaptic mitochondria in the hippocampal CA1 region of the Tg2576 mouse model of Alzheimer's disease. J. Alzheimers Dis. 2013, 34:887-896.
12. Barbiero J.K., et al. Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine. Behav. Brain Res. 2014 Aug 13, 274:C:390-C:399. [Epub ahead of print]. 10.1016/j.bbr.2014.08.014.
13. Becker R.E., Greig N.H. Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?. Alzheimers Dement. 2013, 9:50-57.
14. Bell K.A., et al. MAPK recruitment by beta-amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time. J. Neurochem. 2004, 91:349-361.
15. Benzing W.C., et al. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol. Aging 1999, 20:581-589.
16. Bhat N.R., Thirumangalakudi L. Increased tau phosphorylation and impaired brain insulin/IGF signaling in mice fed a high fat/high cholesterol diet. J. Alzheimers Dis. 2013, 36:781-789.
17. Biddinger S.B., Kahn C.R. From mice to men: insights into the insulin resistance syndromes. Annu. Rev. Physiol. 2006, 68:123-158.
18. Boeve B.F. Mild cognitive impairment associated with underlying Alzheimer's disease versus Lewy body disease. Parkinsonism Relat. Disord. 2012, 18(Suppl. 1):S41-S44.
19. Bomben V., et al. Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy. Neurobiol. Aging 2014, 35:2091-2095.
20. Bonnard C., et al. Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice. J. Clin. Invest. 2008, 118:789-800.
21. Bosco D., et al. Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J. Cell. Mol. Med. 2011, 15:1807-1821.
22. Boura-Halfon S., Zick Y. Serine kinases of insulin receptor substrate proteins. Vitam. Horm. 2009, 80:313-349.
23. Breidert T., et al. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 2002, 82:615-624.
24. Buggia-Prevot V., Thinakaran G. Sorting the role of SORLA in Alzheimer's disease. Sci. Transl. Med. 2014, 6:223fs8.
25. Caccamo A., et al. Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. J. Neurosci. 2014, 34:7988-7998.
26. Camacho I.E., et al. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J. Neurosci. 2004, 24:10908-10917.
27. Carrero I., et al. Oligomers of beta-amyloid protein (Abeta1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interaction with interleukin-1beta, tumour necrosis factor-alpha, and a nuclear factor kappa-B mechanism in the rat brain. Exp. Neurol. 2012, 236:215-227.
28. Caselli R.J., Reiman E.M. Characterizing the preclinical stages of Alzheimer's disease and the prospect of presymptomatic intervention. J. Alzheimers Dis. 2013, 33(Suppl. 1):S405-S416.
29. Castillo-Carranza D.L., et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J. Neurosci. 2014, 34:4260-4272.
30. Cavallucci V., et al. Abeta toxicity in Alzheimer's disease. Mol. Neurobiol. 2012, 45:366-378.
31. Chen J., et al. Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system. Brain Behav. Immun. 2008, 22:301-311.
32. Cheng Z., et al. Insulin signaling meets mitochondria in metabolism. Trends Endocrinol. Metab. 2010, 21:589-598.
33. Cholerton B., et al. Insulin resistance and pathological brain ageing. Diabet. Med. 2011, 28:1463-1475.
34. Choudhary S., et al. NF-kappaB-inducing kinase (NIK) mediates skeletal muscle insulin resistance: blockade by adiponectin. Endocrinology 2011, 152:3622-3627.
35. Combs C.K., et al. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 2000, 20:558-567.
36. Corona A.W., et al. Cognitive and behavioral consequences of impaired immunoregulation in aging. J. NeuroImmune Pharmacol. 2012, 7:7-23.
37. Costello D.A., et al. Agonists of peroxisome proliferator-activated receptor-gamma attenuate the Abeta-mediated impairment of LTP in the hippocampus in vitro. Neuropharmacology 2005, 49:359-366.
38. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch. Neurol. 2009, 66:300-305.
39. Craft S. Alzheimer disease: insulin resistance and AD-extending the translational path. Nat. Rev. Neurol. 2012, 8:360-362.
40. Craft S., Watson G.S. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004, 3:169-178.
41. Craft S., et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998, 50:164-168.
42. Craft S., et al. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch. Gen. Psychiatry 1999, 56:1135-1140.
43. Craft S., et al. Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 1999, 70:146-152.
44. Craft S., et al. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 2003, 28:809-822.
45. Craft J.M., et al. Neuroinflammation: a potential therapeutic target. Expert Opin. Ther. Targets 2005, 9:887-900.
46. Craft S., et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 2012, 69:29-38.
47. Craft S., et al. Insulin and Alzheimer's disease: untangling the web. J. Alzheimers Dis. 2013, 33(Suppl. 1):S263-S275.
48. Cramer P.E., et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
49. Crenshaw D.G., et al. Using genetics to enable studies on the prevention of Alzheimer's disease. Clin. Pharmacol. Ther. 2013, 93:177-185.
50. De Felice F.G., Ferreira S.T. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 2014, 63:2262-2272.
51. De Felice F.G., et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1971-1976.
52. Denner L.A., et al. Cognitive enhancement with rosiglitazone links the hippocampal PPARgamma and ERK MAPK signaling pathways. J. Neurosci. 2012, 32:16725-16735.
53. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 1999, 20:649-688.
54. Dineley K.T., et al. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer's disease. J. Neurosci. 2001, 21:4125-4133.
55. Dineley K.T., et al. Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J. Biol. Chem. 2002, 277:22768-22780.
56. Dineley K.T., et al. Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol. Learn. Mem. 2007, 88:217-224.
57. Dobrowolska J.A., et al. CNS amyloid-beta, soluble APP-alpha and -beta kinetics during BACE inhibition. J. Neurosci. 2014, 34:8336-8346.
58. Dodge H.H., et al. Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease. Alzheimers Dement. 2014 Jul 8, pii: S1552-5260(14)00641-4. http://dx.doi.org/10.1016/j.jalz.2014.04.513 [Epub ahead of print].
59. Dominguez R.O., et al. Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients. Diabetes Res. Clin. Pract. 2012, 98:68-74.
60. Ekonomou A., et al. Stage-specific changes in neurogenic and glial markers in Alzheimer's disease. Biol. Psychiatry 2014 Jun 9, pii: S0006-3223(14)00412-0. http://dx.doi.org.10.1016/j.biopsych.2014.05.021 [Epub ahead of print].
61. English J.D., Sweatt J.D. Activation of p42 mitogen-activated protein kinase in hippocampal long term potentiation. J. Biol. Chem. 1996, 271:24329-24332.
62. English J.D., Sweatt J.D. A requirement for the mitogen-activated protein kinase cascade in hippocampal long term potentiation. J. Biol. Chem. 1997, 272:19103-19106.
63. Escribano L., et al. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem. Biophys. Res. Commun. 2009, 379:406-410.
64. Escribano L., et al. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 2010, 35:1593-1604.
65. Fajas L., et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem. 1997, 272:18779-18789.
66. Farris W., et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4162-4167.
67. Fehm H.L., et al. The selfish brain: competition for energy resources. Hypothalamic Integration of Energy Metabolism 2006, 153:129-140.
68. Feinstein D.L. Therapeutic potential of peroxisome proliferator-activated receptor agonists for neurological disease. Diabetes Technol. Ther. 2003, 5:67-73.
69. Fernandez A.M., Torres-Aleman I. The many faces of insulin-like peptide signalling in the brain. Nat. Rev. Neurosci. 2012, 13:225-239.
70. Ferreira S.T., et al. Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. Alzheimers Dement. 2014, 10:S76-S83.
71. Ferretti M.T., et al. Transgenic mice as a model of pre-clinical Alzheimer's disease. Curr. Alzheimer Res. 2011, 8:4-23.
72. Gasparini L., et al. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 2001, 21:2561-2570.
73. Gele P., et al. Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke. Proteome Sci. 2014, 12:24.
74. 2+/calmodulin-dependent protein kinase II in long-term potentiation. J. Neurosci. 2001, 21:7053-7062.
75. Gold M., et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement. Geriatr. Cogn. Disord. 2010, 30:131-146.
76. Goldin M., Segal M. Protein kinase C and ERK involvement in dendritic spine plasticity in cultured rodent hippocampal neurons. Eur. J. Neurosci. 2003, 17:2529-2539.
77. Goldstein M.E., et al. Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice. J. Pharmacol. Exp. Ther. 2007, 323:102-108.
78. Gong B., et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol. Aging 2013, 34:1581-1588.
79. Gual P., et al. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 2005, 87:99-109.
80. Gupta A., et al. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 2011, 60:910-920.
81. Gupta P.P., et al. Role of traditional nonsteroidal anti-inflammatory drugs in Alzheimer's disease: a meta-analysis of randomized clinical trials. Am. J. Alzheimers Dis. Other Demen. 2014, [Epub ahead of print].
82. Hamann S., et al. Impaired fear conditioning in Alzheimer's disease. Neuropsychologia 2002, 40:1187-1195.
83. Hanyu H., et al. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J. Am. Geriatr. Soc. 2009, 57:177-179.
84. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J. Neurochem. 2009, 110:1129-1134.
85. Hashimoto L., et al. Genetic mapping of a susceptibility locus for insulin-dependent diabetes mellitus on chromosome 11q. Nature 1994, 371:161-164.
86. Hernandez C.M., et al. Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J. Neurosci. 2010, 30:2442-2453.
87. Herrup K., et al. Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease. Alzheimers Dement. 2013, 9:452-458. (e1).
88. Hettich M.M., et al. The anti-diabetic drug metformin reduces BACE1 protein level by interfering with the MID1 complex. PLoS One 2014, 9:e102420.
89. Hirabara S.M., et al. Molecular targets related to inflammation and insulin resistance and potential interventions. J. Biomed. Biotechnol. 2012, 2012:379024.
90. Ho L., et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 2004, 18:902-904.
91. Hoefer M., et al. Fear conditioning in frontotemporal lobar degeneration and Alzheimer's disease. Brain 2008, 131:1646-1657.
92. Hoeks J., Schrauwen P. Muscle mitochondria and insulin resistance: a human perspective. Trends Endocrinol. Metab. 2012, 23:444-450.
93. Hofman A., et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997, 349:151-154.
94. Holland D., et al. Enrichment and stratification for predementia Alzheimer disease clinical trials. PLoS One 2012, 7:e47739.
95. Holtzman D.M., et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2892-2897.
96. Hort J., et al. Spatial navigation deficit in amnestic mild cognitive impairment. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:4042-4047.
97. Hsiao K. Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp. Gerontol. 1998, 33:883-889.
98. Hsiao K., et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
99. Hu Y.S., et al. Complex environment experience rescues impaired neurogenesis, enhances synaptic plasticity, and attenuates neuropathology in familial Alzheimer's disease-linked APPswe/PS1DeltaE9 mice. FASEB J. 2010, 24:1667-1681.
100. Huijbers W., et al. Amyloid deposition is linked to aberrant entorhinal activity among cognitively normal older adults. J. Neurosci. 2014, 34:5200-5210.
101. Hyong A., et al. Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents. Brain Res. 2008, 1215:218-224.
102. Idriss H.T., Naismith J.H. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc. Res. Tech. 2000, 50:184-195.
103. Imfeld P., et al. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. J. Am. Geriatr. Soc. 2012, 60:916-921.
104. Inestrosa N.C., et al. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp. Cell Res. 2005, 304:91-104.
105. Irizarry M.C., et al. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 1997, 56:965-973.
106. Iwen K.A., et al. Intranasal insulin suppresses systemic but not subcutaneous lipolysis in healthy humans. J. Clin. Endocrinol. Metab. 2014, 99:E246-E251.
107. Jack C.R., Holtzman D.M. Biomarker modeling of Alzheimer's disease. Neuron 2013, 80:1347-1358.
108. Jack C.R., et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:257-262.
109. Jack C.R., et al. Evidence for ordering of Alzheimer disease biomarkers. Arch. Neurol. 2011, 68:1526-1535.
110. Jahrling J.B., et al. PPARgamma recruitment to active ERK during memory consolidation is required for Alzheimer's disease-related cognitive enhancement. J. Neurosci. 2014, 34:4054-4063.
111. Jiang Q., et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008, 58:681-693.
112. Jiang L.Y., et al. PPARgamma agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus. CNS Neurosci. Ther. 2012, 18:659-666.
113. Kang S.S., et al. Synthesis and biological evaluation of a library of resveratrol analogues as inhibitors of COX-1, COX-2 and NF-kappaB. Bioorg. Med. Chem. 2009, 17:1044-1054.
114. Kawarabayashi T., et al. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2001, 21:372-381.
115. Kelleher R.J., et al. Translational control by MAPK signaling in long-term synaptic plasticity and memory. Cell 2004, 116:467-479.
116. Kerti L., et al. Higher glucose levels associated with lower memory and reduced hippocampal microstructure. Neurology 2013, 81:1746-1752.
117. Kickstein E., et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21830-21835.
118. Kirpichnikov D., et al. Metformin: an update. Ann. Intern. Med. 2002, 137:25-33.
119. Kleinridders A., et al. Insulin action in brain regulates systemic metabolism and brain function. Diabetes 2014, 63:2232-2243.
120. Kloppenborg R.P., et al. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur. J. Pharmacol. 2008, 585:97-108.
121. Knowler W.C., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002, 346:393-403.
122. Kummer M.P., et al. Pan-PPAR modulation effectively protects APP/PS1 mice from amyloid deposition and cognitive deficits. Mol. Neurobiol. 2014, [Epub ahead of print].
123. Lannert H., Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav. Neurosci. 1998, 112:1199-1208.
124. Lasagna-Reeves C.A., et al. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 2012, 26:1946-1959.
125. Lasagna-Reeves C.A., et al. The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes. Acta Neuropathol. Commun. 2014, 2:56.
126. Lazarov O., et al. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 2005, 120:701-713.
127. Lee P.N. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 1994, 13:131-144.
128. Lee C.Y., et al. Apolipoprotein E promotes beta-amyloid trafficking and degradation by modulating microglial cholesterol levels. J. Biol. Chem. 2012, 287:2032-2044.
129. Leon-Latre M., et al. Sedentary lifestyle and its relation to cardiovascular risk factors, insulin resistance and inflammatory profile. Rev. Esp. Cardiol. 2014, 67:449-455.
130. Lesne S., et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
131. Lester-Coll N., et al. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J. Alzheimers Dis. 2006, 9:13-33.
132. Ley E.J., et al. Diabetic patients with traumatic brain injury: insulin deficiency is associated with increased mortality. J. Trauma 2011, 70:1141-1144.
133. Li X.L., et al. Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 2002, 113:607-615.
134. Li Z.G., et al. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 2007, 56:1817-1824.
135. Li J., et al. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacol. Biochem. Behav. 2012, 101:564-574.
136. Lin A.L., et al. Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease. J. Cereb. Blood Flow Metab. 2013, 33:1412-1421.
137. Long-Smith C.M., et al. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-beta plaque and glial pathology in a mouse model of Alzheimer's disease. NeuroMolecular Med. 2013, 15:102-114.
138. Lonskaya I., et al. Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. J. Mol. Med. (Berl). 2014, 92:373-386.
139. Lowell B.B., Shulman G.I. Mitochondrial dysfunction and type 2 diabetes. Science 2005, 307:384-387.
140. Luchsinger J.A., et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am. J. Epidemiol. 2001, 154:635-641.
141. Luchsinger J.A., et al. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63:1187-1192.
142. Lynch M.A. Long-term potentiation and memory. Physiol. Rev. 2004, 84:87-136.
143. Mandrekar-Colucci S., Landreth G.E. Nuclear receptors as therapeutic targets for Alzheimer's disease. Expert Opin. Ther. Targets 2011, 15:1085-1097.
144. Mandrekar-Colucci S., et al. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J. Neurosci. 2012, 32:10117-10128.
145. Marciano D.P., et al. The therapeutic potential of nuclear receptor modulators for treatment of metabolic disorders: PPARgamma, RORs, and Rev-erbs. Cell Metab. 2014, 19:193-208.
146. Masciopinto F., et al. Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice. Cell Death Dis. 2012, 3:e448.
147. Matsuzaki T., et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 2010, 75:764-770.
148. Mayeux R., Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2.
149. McClean P.L., et al. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 2011, 31:6587-6594.
150. McCoy M.K., Tansey M.G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation 2008, 5:45.
151. McGeer E.G., McGeer P.L. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J. Alzheimers Dis. 2010, 19:355-361.
152. McKhann G.M., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:263-269.
153. Mehlhorn G., et al. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int. J. Dev. Neurosci. 2000, 18:423-431.
154. Mody N., et al. Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1 (A246E) mouse model of Alzheimer's disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein. Diabetologia 2011, 54:2143-2151.
155. Moreno S., et al. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004, 123:131-145.
156. Mowery N.T., et al. Stress insulin resistance is a marker for mortality in traumatic brain injury. J. Trauma 2009, 66:145-151. (discussion 151-3).
157. Musiek E.S., Holtzman D.M. Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Curr. Opin. Neurol. 2012, 25:715-720.
158. Nenov M.N., et al. Cognitive enhancing treatment with a PPARgamma agonist normalizes dentate granule cell presynaptic function in Tg2576 APP mice. J. Neurosci. 2014, 34:1028-1036.
159. Nicolakakis N., et al. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J. Neurosci. 2008, 28:9287-9296.
160. Ong Q.R., et al. Reduced phosphorylation of brain insulin receptor substrate and Akt proteins in apolipoprotein-E4 targeted replacement mice. Sci. Rep. 2014, 4:3754.
161. O'Reilly J.A., Lynch M. Rosiglitazone improves spatial memory and decreases insoluble Abeta(1-42) in APP/PS1 mice. J. Neuroimmune Pharmacol. 2012, 7:140-144.
162. Ott A., et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999, 53:1937-1942.
163. Ozbay L.A., et al. Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers. Br. J. Clin. Pharmacol. 2012, 73:536-545.
164. Palop J.J., Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch. Neurol. 2009, 66:435-440.
165. Palop J.J., et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
166. Park S.A. A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. J. Clin. Neurol. 2011, 7:10-18.
167. Park C.R., et al. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol. Behav. 2000, 68:509-514.
168. Patterson C., et al. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ 2008, 178:548-556.
169. Pedersen W.A., Flynn E.R. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol. Dis. 2004, 17:500-506.
170. Pedersen W.A., et al. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol. 2006, 199:265-273.
171. Pedros I., et al. Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease. Biochim. Biophys. Acta 2014, 1842:1556-1566.
172. Peters F., et al. Predicting progression to dementia in elderly subjects with mild cognitive impairment using both cognitive and neuroimaging predictors. J. Alzheimers Dis. 2014, 38:307-318.
173. Pfrieger F.W., Ungerer N. Cholesterol metabolism in neurons and astrocytes. Prog. Lipid Res. 2011, 50:357-371.
174. Pirttimaki T.M., et al. alpha7 Nicotinic receptor-mediated astrocytic gliotransmitter release: Abeta effects in a preclinical Alzheimer's mouse model. PLoS One 2013, 8:e81828.
175. Pisanu A., et al. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-gamma agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease. Neurobiol. Dis. 2014, [Epub ahead of print].
176. Plaschke K., et al. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. J. Alzheimers Dis. 2010, 19:691-704.
177. Polito L., et al. Environmental enrichment lessens cognitive decline in APP23 mice without affecting brain sirtuin expression. J. Alzheimers Dis. 2014, [Epub ahead of print].
178. Porrini E., et al. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. Nephrol. Dial. Transplant. 2008, 23:1436-1441.
179. Prakash A., Kumar A. Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of beta-amyloid animal model of Alzheimer's disease. Neurotox. Res. 2014, 25:335-347.
180. Putcha D., et al. Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults. J. Neurosci. 2011, 31:17680-17688.
181. Qu Z., et al. Effects of streptozotocin-induced diabetes on tau phosphorylation in the rat brain. Brain Res. 2011, 1383:300-306.
182. Reiman E.M., et al. Alzheimer's disease: implications of the updated diagnostic and research criteria. J. Clin. Psychiatry 2011, 72:1190-1196.
183. Reitz C., Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol. 2014, [Epub ahead of print].
184. Ridder D.A., Schwaninger M. In search of the neuroprotective mechanism of thiazolidinediones in Parkinson's disease. Exp. Neurol. 2012, 238:133-137.
185. Risner M.E., et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006, 6:246-254.
186. Rivera E.J., et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J. Alzheimers Dis. 2005, 8:247-268.
187. Rockenstein E., et al. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J. Neurosci. Res. 2006, 83:1252-1261.
188. Rodriguez-Rivera J., et al. Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status. Behav. Brain Res. 2011, 216:255-261.
189. Rohe M., et al. Brain-derived neurotrophic factor reduces amyloidogenic processing through control of SORLA gene expression. J. Neurosci. 2009, 29:15472-15478.
190. Sabbagh J.J., et al. Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications. Neurobiol. Aging 2013, 34:169-183.
191. Sadigh-Eteghad S., et al. Association of apolipoprotein E epsilon 4 allele with sporadic late onset Alzheimer's disease. A meta-analysis. Neurosciences (Riyadh) 2012, 17:321-326.
192. Saha A.K., et al. Downregulation of AMPK accompanies leucine- and glucose-induced increases in protein synthesis and insulin resistance in rat skeletal muscle. Diabetes 2010, 59:2426-2434.
193. Salminen A., et al. AMP-activated protein kinase: a potential player in Alzheimer's disease. J. Neurochem. 2011, 118:460-474.
194. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
195. Samson S.L., Garber A.J. Metabolic syndrome. Endocrinol. Metab. Clin. North Am. 2014, 43:1-23.
196. Samuel V.T., Shulman G.I. Mechanisms for insulin resistance: common threads and missing links. Cell 2012, 148:852-871.
197. Sarruf D.A., et al. Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology 2009, 150:707-712.
198. Sato T., et al. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol. Aging 2011, 32:1626-1633.
199. Sauerbeck A., et al. Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Exp. Neurol. 2011, 227:128-135.
200. Schioth H.B., et al. Brain insulin signaling and Alzheimer's disease: current evidence and future directions. Mol. Neurobiol. 2012, 46:4-10.
201. Schrijvers E.M., et al. Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology 2010, 75:1982-1987.
202. Searcy J.L., et al. Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. J. Alzheimers Dis. 2012, [Epub ahead of print].
203. Selcher J.C., et al. A necessity for MAP kinase activation in mammalian spatial learning. Learn. Mem. 1999, 6:478-490.
204. Selcher J.C., et al. Mice lacking the ERK1 isoform of MAP kinase are unimpaired in emotional learning. Learn. Mem. 2001, 8:11-19.
205. Shaham O., et al. Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol. Syst. Biol. 2008, 4:214.
206. Sheng L., et al. NF-kappaB-inducing kinase (NIK) promotes hyperglycemia and glucose intolerance in obesity by augmenting glucagon action. Nat. Med. 2012, 18:943-949.
207. Sims-Robinson C., et al. How does diabetes accelerate Alzheimer disease pathology?. Nat. Rev. Neurol. 2010, 6:551-559.
208. Singh J.P., et al. Explicit role of peroxisome proliferator-activated receptor gamma in gallic acid-mediated protection against ischemia-reperfusion-induced acute kidney injury in rats. J. Surg. Res. 2014, 187:631-639.
209. Skerrett R., et al. Nuclear receptors in neurodegenerative diseases. Neurobiol. Dis. 2014, [Epub ahead of print].
210. Slooter A.J., et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch. Neurol. 1998, 55:964-968.
211. Sparks D.L., et al. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 1994, 126:88-94.
212. Sparks D.L., et al. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J. Neurol. Sci. 1995, 131:162-169.
213. Sperling R.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
214. Steen E., et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7:63-80.
215. Stockhorst U., et al. Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiol. Behav. 2004, 83:47-54.
216. Stoica L., et al. Selective pharmacogenetic inhibition of mammalian target of Rapamycin complex I (mTORC1) blocks long-term synaptic plasticity and memory storage. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3791-3796.
217. Strittmatter W.J., et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:8098-8102.
218. Sun X.J., Liu F. Phosphorylation of IRS proteins Yin-Yang regulation of insulin signaling. Vitam. Horm. 2009, 80:351-387.
219. Sutinen E.M., et al. Pro-inflammatory interleukin-18 increases Alzheimer's disease-associated amyloid-beta production in human neuron-like cells. J. Neuroinflammation 2012, 9:199.
220. Swardfager W., et al. A meta-analysis of cytokines in Alzheimer's disease. Biol. Psychiatry 2010, 68:930-941.
221. Sweatt J.D. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J. Neurochem. 2001, 76:1-10.
222. Sweatt J.D. Mitogen-activated protein kinases in synaptic plasticity and memory. Curr. Opin. Neurobiol. 2004, 14:311-317.
223. Szekely C.A., et al. Prevention of Alzheimer's disease. Int. Rev. Psychiatry 2007, 19:693-706.
224. Taglialatela G., et al. Intermediate- and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition. Behav. Brain Res. 2009, 200:95-99.
225. Taguchi A., White M.F. Insulin-like signaling, nutrient homeostasis, and life span. Annu. Rev. Physiol. 2008, 70:191-212.
226. Takeda S., et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7036-7041.
227. Talbot K., et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 2012, 122:1316-1338.
228. Tanti J.F., Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr. Opin. Pharmacol. 2009, 9:753-762.
229. Thal S.C., et al. Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-gamma-independent mechanisms. J. Neurotrauma 2011, 28:983-993.
230. Thies W., et al. 2013 Alzheimer's disease facts and figures. Alzheimers Dement. 2013, 9:208-245.
231. Tillu D.V., et al. Resveratrol engages AMPK to attenuate ERK and mTOR signaling in sensory neurons and inhibits incision-induced acute and chronic pain. Mol. Pain 2012, 8:5.
232. Tsatsoulis A., et al. Insulin resistance: an adaptive mechanism becomes maladaptive in the current environment - an evolutionary perspective. Metabolism 2013, 62:622-633.
233. Turner N., Heilbronn L.K. Is mitochondrial dysfunction a cause of insulin resistance?. Trends Endocrinol. Metab. 2008, 19:324-330.
234. Udayar V., et al. A paired RNAi and RabGAP overexpression screen identifies Rab11 as a regulator of beta-amyloid production. Cell Rep. 2013, 5:1536-1551.
235. Vadas O., et al. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci. Signal. 2011, 4:re2.
236. van Himbergen T.M., et al. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease: results from the Framingham Heart Study. Arch. Neurol. 2012, 69:594-600.
237. Vellas B., et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012, 11:851-859.
238. Victor N.A., et al. Altered PPARgamma expression and activation after transient focal ischemia in rats. Eur. J. Neurosci. 2006, 24:1653-1663.
239. Vossel K.A., et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013, 70:1158-1166.
240. Wallum B.J., et al. Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man. J. Clin. Endocrinol. Metab. 1987, 64:190-194.
241. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
242. Wang Z., et al. Persistent ERK phosphorylation negatively regulates cAMP response element-binding protein (CREB) activity via recruitment of CREB-binding protein to pp90RSK. J. Biol. Chem. 2003, 278:11138-11144.
243. Watson G.S., Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 2003, 17:27-45.
244. Watson G.S., et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 2005, 13:950-958.
245. Watson G.S., et al. Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease. Neurobiol. Aging 2006, 27:38-41.
246. Webster S.J., et al. Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front. Genet. 2014, 5:88.
247. Werther G.A., et al. Localization and characterization of insulin receptors in rat brain and pituitary gland using in vitro autoradiography and computerized densitometry. Endocrinology 1987, 121:1562-1570.
248. Westerman M.A., et al. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 2002, 22:1858-1867.
249. White M.F. Insulin signaling in health and disease. Science 2003, 302:1710-1711.
250. Wickelgren I. Tracking insulin to the mind. Science 1998, 280:517-519.
251. Wildsmith K.R., et al. Evidence for impaired amyloid beta clearance in Alzheimer's disease. Alzheimers Res. Ther. 2013, 5:33.
252. Winder D.G., et al. ERK plays a regulatory role in induction of LTP by theta frequency stimulation and its modulation by beta-adrenergic receptors. Neuron 1999, 24:715-726.
253. Woods S.C., et al. Insulin and the blood-brain barrier. Curr. Pharm. Des. 2003, 9:795-800.
254. Wortzel I., Seger R. The ERK cascade: distinct functions within various subcellular organelles. Genes Cancer 2011, 2:195-209.
255. Wu G.Y., et al. Spaced stimuli stabilize MAPK pathway activation and its effects on dendritic morphology. Nat. Neurosci. 2001, 4:151-158.
256. Xia Z.G., Storm D.R. Role of signal transduction crosstalk between adenylyl cyclase and MAP kinase in hippocampus-dependent memory. Learn. Mem. 2012, 19:369-374.
257. Xu W.L., et al. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004, 63:1181-1186.
258. Yarchoan M., Arnold S.E. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 2014, 63:2253-2261.
259. Yarchoan M., et al. Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. Acta Neuropathol. 2014, [Epub ahead of print].
260. Yin Q.Q., et al. Pioglitazone improves cognitive function via increasing insulin sensitivity and strengthening antioxidant defense system in fructose-drinking insulin resistance rats. PLoS One 2013, 8:e59313.
261. Zhao W.Q., et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008, 22:246-260.